


## VENTANA PD-L1 (SP142) Assay



<b>Catalog Number:</b>	741-4860
<b>Ordering Code:</b>	08008540001
<b>Quantity:</b>	50 tests
<b>Controls:</b>	Tonsil
<b>Isotypes:</b>	IgG
<b>Clone Name:</b>	SP142
<b>Species:</b>	Rabbit
<b>Localization:</b>	Membranous and/or Cytoplasmic Staining
<b>Regulatory Status:</b>	CE-IVD

VENTANA PD-L1 (SP142) Assay is intended for the immunohistochemical assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tissues indicated below stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a BenchMark IHC/ISH instrument.

Determination of PD-L1 status is indication-specific and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.

VENTANA PD-L1 (SP142) Assay is indicated as an aid for identifying patients for treatment with the therapies listed in Table 1 for the respective indications and cutoffs in accordance with the approved therapeutic product labeling.

VENTANA PD-L1 (SP142) Assay may be associated with enhanced patient benefit with the therapies listed in Table 2 for the corresponding indication and cutoffs in accordance with the approved therapeutic product labeling.

**Table 1.** VENTANA PD-L1 (SP142) Assay companion diagnostic indications.

Indication for use	Therapy	Cutoff
Urothelial Carcinoma	TECENTRIQ	≥5% IC
Triple-Negative Breast Carcinoma (TNBC)	TECENTRIQ	≥1% IC

**Table 2.** VENTANA PD-L1 (SP142) Assay complementary diagnostic indication.

Indication for use	Therapy	Cutoff
	TECENTRIQ	≥ 50% TC or ≥ 10% IC

Non-small Cell Lung Cancer  
(NSCLC)

≥ 1% TC or ≥ 1% IC

Test results of this product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This product is intended for *in vitro* diagnostic (IVD) use.

**[WEBSITE TERMS & CONDITIONS](#)**   **[PRIVACY NOTICE](#)**   **[COOKIE POLICY](#)**   **[CALIFORNIA'S TRAN](#)**

This website contains information on products which is targeted to a wide range of audiences and could be not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing any legal process, regulation, registration or usage in the country of your origin.

© 2019 F. Hoffmann-La Roche Ltd  
27.07.2018

Cookies Notice

This website uses cookies to provide you with an improved and personalized experience. By using this site you agree to our use of cookies. Please read our [cookie policy](#) for more information on the cookies we use and how to delete or block them.

I Accept

X

Health Care Provider Notice

X

This website is intended for healthcare professionals only.

The content on this website is intended for healthcare professionals only. Information intended for the general public can be found on [Roche.com](#). *Please confirm that you are a medical professional before accessing the content of this website.*

Yes, I hereby certify that I am a healthcare professional. [Continue](#)

Third-Party Link Disclosure

X

Disclosure for Links to Third-Party Websites

You are now leaving the Roche website. The site you are about to visit is operated by third-parties. The link to this site neither makes nor implies any representation or warranty for any products or services offered on a third-party site and is intended only to enable convenient access to the third-party site and for no other purpose.

[Continue](#)